Document Detail


The dexamethasone drug delivery system: indications and evidence.
MedLine Citation:
PMID:  21494891     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: The Ozurdex(®) (Allergan Inc., Irvine, CA, USA) dexamethasone drug delivery system (DDS) was recently developed as a biodegradable intravitreal implant to provide sustained delivery of 700 μg of preservativefree dexamethasone to the retina and vitreous, and is approved by the United States Food and Drug Administration (FDA) for the treatment of macular edema associated with retinal vein occlusion, as well as for noninfectious posterior uveitis. This review summarizes the rationale behind the development of the dexamethasone DDS, evidence for its use in various clinical scenarios, and compares its efficacy to other available treatment options.
METHODS: Published data regarding the dexamethasone DDS as well as unpublished data that has been presented at national meetings were reviewed.
RESULTS: The dexamethasone DDS has evidence for efficacy in multiple clinical situations, including macular edema associated with retinal vein occlusion (RVO), macular edema associated with uveitis or Irvine-Gass syndrome, diabetic macular edema in vitrectomized eyes, persistent macular edema, noninfectious vitritis, and as adjunctive therapy for age-related macular degeneration. Safety concerns include cataract formation and intraocular pressure elevation that is most often temporary and amenable to medical management.
CONCLUSIONS: The dexamethasone DDS is one of the most recent additions to the armamentarium against macular edema, and is intriguing for its potency, dose consistency, potential for extended duration of action, and favorable safety profile. Early evidence shows clinical utility for several conditions, the most well established being for macular edema associated with RVO. Future studies and, in particular, head-to-head comparisons with other treatment modalities will elucidate the precise role for the dexamethasone DDS in clinical practice.
Authors:
Nikolas J S London; Allen Chiang; Julia A Haller
Publication Detail:
Type:  Journal Article; Review     Date:  2011-03-12
Journal Detail:
Title:  Advances in therapy     Volume:  28     ISSN:  1865-8652     ISO Abbreviation:  Adv Ther     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-05-16     Completed Date:  2011-10-03     Revised Date:  2013-08-30    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  351-66     Citation Subset:  T    
Affiliation:
Retina Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents / administration & dosage,  adverse effects
Dexamethasone / administration & dosage*,  adverse effects
Drug Delivery Systems / methods*
Drug Implants
Humans
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Drug Implants; 50-02-2/Dexamethasone
Comments/Corrections
Erratum In:
Adv Ther. 2013 Jun;30(6):644

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  CO(2) laser of oral dysplasia: clinicopathological features of recurrence and malignant transformati...
Next Document:  Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of t...